Healthcare Industry News:  Multiplexed ICE COLD-PCR 

Diagnostics Product Launch

 News Release - July 14, 2015

Transgenomic Launches Most Comprehensive Genetic Test for Diagnosis of Leukodystrophy

New Test is Most Comprehensive for Definitive Diagnosis of These Devastating Genetic Disorders

OMAHA, Neb.--(Healthcare Sales & Marketing Network)--Transgenomic, Inc. (TBIO), a global biotechnology company advancing precision medicine through advanced diagnostic tests and clinical and research services, today announced the launch of the Transgenomic Leukodystrophy NGS Panel for the diagnosis of leukodystrophy, a group of rare progressive genetic disorders that affect the central nervous system by disrupting the growth or maintenance of the myelin sheath insulating nerve cells.

Leukodystrophies have typically been difficult to diagnose, with definitive diagnoses taking years of testing. Previously, brain MRI scans were commonly used, but often provided non-specific results. With the advent of improved genetic testing methods, the Global Leukodystrophy Initiative (GLIA) Consortium has issued diagnostic guidelines that recommend use of a broad spectrum next-generation sequencing (NGS) panel, whole exome sequencing, or whole genome sequencing as the preferred first-line diagnostic tool. The new Transgenomic Leukodystrophy NGS Panel includes 137 genes and incorporates all of the genes GLIA recommends for testing. As the most comprehensive test on the market, it can potentially make definitive diagnoses accessible to patients and their families much earlier in the disease process.

“Leukodystrophy comprises a group of devastating genetic diseases that have been difficult to diagnose and almost impossible to treat,” said Paul Kinnon, President and Chief Executive Officer of Transgenomic. “We accordingly are very pleased to launch our Leukodystrophy NGS Panel, the most comprehensive genetic test for these conditions available today. By enabling clinicians to pinpoint the genetic source of the disorder earlier in the disease, we hope the Leukodystrophy NGS Panel will enable better disease management and facilitate the development of more effective therapies using new technologies, such as stem cells or gene editing techniques. This new test is another example of our commitment to harnessing advanced genetic tools to improve the lives of patients and families.”

The leukodystrophies are a group of about 40 inherited conditions in which the white matter of the brain is abnormal as a result of altered development or degeneration of the myelin sheath, the fatty covering that protects neurons. The condition results in progressive loss of neurologic function. Leukodystrophies often appear during infancy or early childhood, although the disease occasionally first manifests in adults. Diagnosis has typically been made by brain MRI, but many of the findings are non-specific. Most leukodystrophies result in progressive disability and death, often in childhood. Bone marrow transplantation is being performed for a few leukodystrophies, but current treatment is primarily supportive.

Robert Rauner, President of the United Leukodystrophy Foundation, commented, “On average it can take up to a decade to arrive at a definitive diagnosis for a leukodystrophy. Transgenomic’s genetic testing panel may help affected individuals arrive at a definitive diagnosis earlier to guide patient management decisions. This is very positive for those affected by leukodystrophy.”

For more information on the Transgenomic Leukodystrophy NGS Panel, visit

Transgenomic, Inc. is a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through advanced diagnostic technologies, such as its revolutionary ICE COLD-PCR™ and its unique genetic tests provided through its Patient Testing business. Transgenomic also provides specialized clinical and research services to biopharmaceutical companies developing targeted therapies and sells equipment, reagents and other consumables for applications in molecular testing and cytogenetics. Transgenomic’s diagnostic technologies are designed to improve medical diagnoses and patient outcomes.

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements” of Transgenomic within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements include, but are not limited to, those with respect to the expected timing for the availability of additional mutations with the ICEme kits, the potential uses for the ICEme kits, the effectiveness of the ICEme kits and Multiplexed ICE COLD-PCR technology, the availability of the ICEme kits for diagnostic use and expectations regarding the ICEme kits’ and Multiplexed ICE COLD-PCR’s ability to facilitate the development of Transgenomic’s pipeline. The known risks, uncertainties and other factors affecting these forward-looking statements are described from time to time in Transgenomic's filings with the Securities and Exchange Commission, including in Transgenomic’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission on April 15, 2015. Any change in such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred to in such statements. Accordingly, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 with respect to all statements contained in this press release. All information in this press release is as of the date of the release and Transgenomic does not undertake any duty to update this information, including any forward-looking statements, unless required by law.

Source: Transgenomic

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.